GlassScriptPhysician profile
Da Young Kim
NPI 1649912296
$1,657.76
in general payments reported to CMS, 2019-2025
13 companies · $897 in 2025
The $897 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $761 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $318.78 | 2025 | |
| Jazz Pharmaceuticals INC. | $288.80 | 2024-2025 | |
| Ucb, INC. | $247.75 | 2024-2025 | Fintepla, Rystiggo |
| Tg Therapeutics, INC. | $228.17 | 2024-2025 | |
| Amgen INC. | $123.06 | 2024 | Uplizna |
| Ceribell, INC. | $110.78 | 2024 | Pocket Eeg Device |
| Neurelis, INC. | $109.38 | 2024 | Valtoco |
| Neuropace, INC. | $99.02 | 2025 | |
| Vanda Pharmaceuticals INC. | $31.90 | 2025 | Ponvory |
| Pfizer INC. | $29.88 | 2025 | |
| Merz Pharmaceuticals, LLC | $28.52 | 2024 | Xeomin |
| Ani Pharmaceuticals, INC. | $26.50 | 2025 | Purified Cortrophin Gel |
| Cycle Pharmaceuticals INC | $15.22 | 2025 | Bafiertam, Tascenso Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Da Young Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.